Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway

Fengli Zhang; Huixiao Chen; Jing Du; Bin Wang; Lixiao Yang

doi:10.12659/MSM.932331

Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway

Med Sci Monit. 2021 Mar 25:27:e932331. doi: 10.12659/MSM.932331.

Authors

Fengli Zhang^{1

2}, Huixiao Chen², Jing Du², Bin Wang², Lixiao Yang²

Affiliations

¹ Infertility Center, Qilu Hospital, Shandong University, Jinan, Shandong, China (mainland).
² Department of Obstetrics and Gynecology, Liaocheng People's Hospital, Liaocheng, Shandong, China (mainland).

Abstract

An editorial decision has been made to retract this manuscript due to breach of publishing guidelines, following the identification of non-original and manipulated figures. Reference: Fengli Zhang, Huixiao Chen, Jing Du, Bin Wang, Lixiao Yang: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit 2018; 24: 6093-6101. 10.12659/MSM.909745.

Publication types

Retraction of Publication